Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma

Melissa Bennett; Melinda Tea; Briony Gliddon; John Toubia; Robert Orlowski; Craig Wallington-Beddoe; Stuart Pitson

doi:10.1016/j.exphem.2019.06.329

Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma

Melissa Bennett
, Melinda Tea
, Briony Gliddon
, John Toubia
, Robert Orlowski
, Craig Wallington-Beddoe
, Stuart Pitson

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism.

Original language	English
Article number	3019
Pages (from-to)	S58
Number of pages	1
Journal	Experimental Hematology
Volume	76
Issue number	Supplement
DOIs	https://doi.org/10.1016/j.exphem.2019.06.329
Publication status	Published - 2019
Event	48th ISEH Annual Scientific Meeting - Brisbane Convention & Exhibition Centre, Brisbane, Australia Duration: 22 Aug 2019 → 25 Aug 2019

Keywords

multiple myeloma
Sphingosine kinase 2
Bortezomib resistance
5TGM1
K145

Access to Document

10.1016/j.exphem.2019.06.329Licence: In Copyright

Cite this

@article{1a4c2efb2dca4e10bff636272af96dc9,

title = "Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma",

abstract = "Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism. ",

keywords = "multiple myeloma, Sphingosine kinase 2, Bortezomib resistance, 5TGM1, K145",

author = "Melissa Bennett and Melinda Tea and Briony Gliddon and John Toubia and Robert Orlowski and Craig Wallington-Beddoe and Stuart Pitson",

year = "2019",

doi = "10.1016/j.exphem.2019.06.329",

language = "English",

volume = "76",

pages = "S58",

journal = "Experimental Hematology",

issn = "0301-472X",

publisher = "Elsevier Inc.",

number = "Supplement",

note = "48th ISEH Annual Scientific Meeting, ISEH Brisbane 2019 ; Conference date: 22-08-2019 Through 25-08-2019",

}

TY - JOUR

T1 - Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma

AU - Bennett, Melissa

AU - Tea, Melinda

AU - Gliddon, Briony

AU - Toubia, John

AU - Orlowski, Robert

AU - Wallington-Beddoe, Craig

AU - Pitson, Stuart

PY - 2019

Y1 - 2019

N2 - Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism.

AB - Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism.

KW - multiple myeloma

KW - Sphingosine kinase 2

KW - Bortezomib resistance

KW - 5TGM1

KW - K145

U2 - 10.1016/j.exphem.2019.06.329

DO - 10.1016/j.exphem.2019.06.329

M3 - Meeting Abstract

SN - 0301-472X

VL - 76

SP - S58

JO - Experimental Hematology

JF - Experimental Hematology

IS - Supplement

M1 - 3019

T2 - 48th ISEH Annual Scientific Meeting

Y2 - 22 August 2019 through 25 August 2019

ER -

Inhibition of sphingosine kinase 2 resensitises bortezomib-resistant multiple myeloma

Abstract

Keywords

Access to Document

Fingerprint

Cite this